Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Drugs Ethical Standards

 
 
Drug promotion can significantly influence the way medicines are prescribed, dispensed and used. It can lead to over-prescribing and poor quality  prescribing and medicine use which, in turn, can lead to increased risks of adverse effects and higher health-care costs. The World Health Organization established the Ethical Criteria for Medicinal Drug Promotion which defines promotion as "all informational and persuasive activities of manufacturers and distributors that affect the prescription, supply, purchase and/or use of medicinal drugs".
The Lebanese Ministry of Public Health worked on adapting these criteria to national circumstances with the help of all relevant stakeholders under the leadership of Dr. Walid Ammar- General Director of the ministry to have a comprehensive code of ethics to prevent the provision of inaccurate and misleading information and promote the rational use of medicines.
The code of ethics provides guidance for health professionals on how to manage their interactions with industry and guidance for industry about how to implement their marketing practices to establish transparency and accountability in pharmaceutical promotion.
The code is now ready to be launched after it was finalized as a result of a wide participatory process that lasted for 2 years with all relevant stakeholders
 
 

 
    2
ATC Name B/G Ingredients Dosage Form Price
C03CA01 URO-CARE G Furosemide - 20mg/2ml 20mg/2ml Injectable solution 1,630,081 L.L
G04BC URALYT-U B Potassium Sodium Hydrogen Citrate - 2427.7mg 2427.7mg Granules 1,351,906 L.L
A05AA02 URSOFALK B Ursodeoxycholic acid - 250mg 250mg Capsule 2,823,413 L.L
N01AH06 ULTIVA B Remifentanil (HCl) - 2mg 2mg Injectable powder for solution 1,632,769 L.L
A12BA02 UROKIT G Potassium Citrate - 3g 3g Powder for solution 1,628,737 L.L
B01AC27 UPTRAVI B Selexipag - 400mcg 400mcg Tablet, film coated 275,097,581 L.L
V03AF01 UROMITEXAN B Mesna - 400mg/4ml 400mg/4ml Injectable solution 2,632,587 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 895,895 L.L
A02BC01 ULCAZAL G Omeprazole (sodium) - 40mg 40mg Injectable sterile lyophilised powder for solution 5,916,747 L.L
R03DC03 UNICAST G Montelukast (sodium) - 4mg 4mg Tablet, chewable 783,460 L.L
C02CA04 UNIPROST G Doxazosin - 4mg 4mg Tablet 452,875 L.L
L01XX05 UNIDREA G Hydroxycarbamide (or Hydroxyurea) - 500mg 500mg Capsule, hard 2,539,862 L.L
A07FA02 ULTRA LEVURE B Saccharomyces boulardii - 50mg 50mg Capsule 381,651 L.L
R03DC03 UNICAST G Montelukast (sodium) - 5mg 5mg Tablet, chewable 783,460 L.L
N01AH06 ULTIVA B Remifentanil (HCl) - 5mg 5mg Injectable powder for solution 2,990,050 L.L
G04BD08 URICARE G Solifenacin succinate - 5mg 5mg Tablet, film coated 1,334,884 L.L
G04BD08 URISOL G Solifenacin succinate - 5mg 5mg Tablet, film coated 1,334,884 L.L
B01AC27 UPTRAVI B Selexipag - 600mcg 600mcg Tablet, film coated 275,097,581 L.L
J07AX URO-VAXOM B Lyophilized bacterial lysates of E-Coli - 6mg 6mg Capsule 2,689,029 L.L
B01AC27 UPTRAVI B Selexipag - 800mcg 800mcg Tablet, film coated 275,097,581 L.L
    2
Sitemap
© Copyrights reserved to Ministry of Public Health 2025